Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.62 |
| ▸ | LCK | P06239 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | CA12 | O43570 | 2/20 | 0.33 |
| ▸ | CA1 | P00915 | 2/20 | 0.33 |
| ▸ | CA9 | Q16790 | 2/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | KDM5A | P29375 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.32 |
| ▸ | DRD3 | P35462 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL151280 | 0.92 | TSHR (0.57) | TSHRLCKALDH1A1TDP1MAPT | |
| SCHEMBL11141675 | 0.91 | TSHR (0.56) | TSHRLCKKDM5AKCNH2 | |
| SCHEMBL10937095 | 0.90 | LCK (0.58) | TSHRLCKALDH1A1CA12CA1 | |
| SCHEMBL152635 | 0.90 | LCK (0.58) | TSHRLCKALDH1A1CA12CA1 | |
| SCHEMBL11668634 | 0.88 | LCK (0.56) | TSHRLCKALDH1A1CA12CA1 | |
| SCHEMBL27855256 | 0.88 | TSHR (0.48) | TSHRLCK | |
| SCHEMBL23388983 | 0.87 | LCK (0.56) | TSHRLCKALDH1A1TDP1MAPT | |
| SCHEMBL3456784 | 0.83 | TSHR (0.52) | TSHRLCKALDH1A1TDP1MAPT | |
| SCHEMBL7710167 | 0.83 | LCK (0.56) | TSHRLCKCA12CA1KDM5A | |
| SCHEMBL153175 | 0.82 | TSHR (0.50) | TSHRLCKALDH1A1TDP1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2526149-B1 | POLYMERS FUNCTIONALIZED WITH NITRILE COMPOUNDS CONTAINING A PROTECTED AMINO GROUP | BRIDGESTONE CORP (JP) | 2017-03-01 | — | — | EP | disclosed |
| US-9469710-B2 | Polymers functionalized with nitrile compounds containing a protected amino group | BRIDGESTONE CORPORATION (JP) | 2016-10-18 | — | — | US | disclosed |
| US-20150148489-A1 | POLYMERS FUNCTIONALIZED WITH NITRILE COMPOUNDS CONTAINING A PROTECTED AMINO GROUP | BRIDGESTONE CORPORATION (JP) | 2015-05-28 | — | — | US | disclosed |
| US-8735494-B2 | Polymers functionalized with nitrile compounds containing a protected amino group | BRIDGESTONE CORPORATION (JP) | 2014-05-27 | — | — | US | disclosed |
| US-20130085227-A1 | POLYMERS FUNCTIONALIZED WITH NITRILE COMPOUNDS CONTAINING A PROTECTED AMINO GROUP | BRIDGESTONE CORPORATION (JP) | 2013-04-04 | — | — | US | disclosed |
| US-8344066-B2 | Polymers functionalized with nitrile compounds containing a protected amino group | BRIDGESTONE CORPORATION (JP) | 2013-01-01 | — | — | US | disclosed |
| US-20120296041-A1 | POLYMERS FUNCTIONALIZED WITH NITRILE COMPOUNDS CONTAINING A PROTECTED AMINO GROUP | BRIDGESTONE CORPORATION (JP) | 2012-11-22 | — | — | US | disclosed |
| US-20120059112-A1 | POLYMERS FUNCTIONALIZED WITH NITRILE COMPOUNDS COMTAINING A PROTECTED AMINO GROUP | BRIDGESTONE CORPORATION (JP) | 2012-03-08 | — | — | US | disclosed |
| US-20120015925-A1 | NOVEL BENZOTHIAZEPINE AND BENZOTHIEPINE COMPOUNDS | ASAHI KASEI PHARMA CORPORATION (JP) | 2012-01-19 | — | — | US | disclosed |
| EP-2382240-A2 | POLYMERS FUNCTIONALIZED WITH NITRILE COMPOUNDS CONTAINING A PROTECTED AMINO GROUP | Bridgestone Corporation (JP) | 2011-11-02 | — | — | EP | disclosed |
| WO-2011091346-A2 | POLYMERS FUNCTIONALIZED WITH NITRILE COMPOUNDS CONTAINING A PROTECTED AMINO GROUP | BRIDGESTONE CORPORATION (JP) | 2011-07-28 | — | — | WO | disclosed |
| US-7973030-B2 | Benzothiazepine and benzothiepine compounds | ASAHI KASEI PHARMA CORPORATION (JP) | 2011-07-05 | — | — | US | disclosed |
| WO-2010085622-A9 | POLYMERS FUNCTIONALIZED WITH NITRILE COMPOUNDS CONTAINING A PROTECTED AMINO GROUP | BRIDGESTONE CORPORATION (JP) | 2010-12-23 | — | — | WO | disclosed |
| US-7803792-B2 | Quaternary ammonium compounds | ASAHI KASEI PHARMA CORPORATION (JP) | 2010-09-28 | — | — | US | disclosed |
| WO-2010085622-A2 | POLYMERS FUNCTIONALIZED WITH NITRILE COMPOUNDS CONTAINING A PROTECTED AMINO GROUP | BRIDGESTONE CORPORATION (JP) | 2010-07-29 | — | — | WO | disclosed |
| US-7312208-B2 | Quaternary ammonium compounds | ASAHI KASEI PHARMA CORPORATION (JP) | 2007-12-25 | — | — | US | disclosed |
| US-20070203115-A1 | Novel quaternary ammonium compounds | ASAHI KASEI PHARMA CORPORATION (JP) | 2007-08-30 | — | — | US | disclosed |
| US-20070190041-A1 | Novel benzothiazepine and bensothiepine compounds | ASHAI KASEI PHARAMA CORPORATION (JP) | 2007-08-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070203115-A1 | Novel quaternary ammonium compounds | SLC10A2, SLC10A1, ABCB11 | TSHR 3847/4885LCK 4017/4885ALDH1A1 2165/4885 |
| US-20120015925-A1 | NOVEL BENZOTHIAZEPINE AND BENZOTHIEPINE COMPOUNDS | SLC10A1, SREBF1, SPTLC1 | TSHR 3208/4885LCK 4530/4885ALDH1A1 1261/4885 |
| US-20070190041-A1 | Novel benzothiazepine and bensothiepine compounds | SLC10A1, GOT1, CES1 | TSHR 2972/4885LCK 4701/4885ALDH1A1 680/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.